August 21, 2009
An Undervalued Hidden Gem
The Fool writes that one of their Hidden Gems selections, Innophos Holdings appears to be cheap with its 2.1 P/E ratio and 2.4 P/FCF ratio.
August 17, 2009
The Case for Stryker
The Fool makes a good case for owning Stryker in this article. The company is an official Inside Value selection and the Fool owns shares of the company.
August 11, 2009
$30 Price Target on Human Genome Sciences
Notables Calls notes that Leerink has set a new price target of $30 on Human Genome Sciences due to the likely hood of positive Phase II trial data for BLISS-76.
August 5, 2009
Subscribe to:
Posts (Atom)
